FI3384049T3 - Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä - Google Patents
Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä Download PDFInfo
- Publication number
- FI3384049T3 FI3384049T3 FIEP16823372.4T FI16823372T FI3384049T3 FI 3384049 T3 FI3384049 T3 FI 3384049T3 FI 16823372 T FI16823372 T FI 16823372T FI 3384049 T3 FI3384049 T3 FI 3384049T3
- Authority
- FI
- Finland
- Prior art keywords
- vegf inhibitor
- patient
- use according
- vegf
- single nucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Data Mining & Analysis (AREA)
- Primary Health Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Ophthalmology & Optometry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262589P | 2015-12-03 | 2015-12-03 | |
| US201662291274P | 2016-02-04 | 2016-02-04 | |
| PCT/US2016/064403 WO2017096031A1 (en) | 2015-12-03 | 2016-12-01 | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3384049T3 true FI3384049T3 (fi) | 2023-09-25 |
Family
ID=57758695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP16823372.4T FI3384049T3 (fi) | 2015-12-03 | 2016-12-01 | Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11769597B2 (https=) |
| EP (3) | EP4559524A3 (https=) |
| JP (5) | JP6855480B2 (https=) |
| KR (4) | KR102183910B1 (https=) |
| CN (2) | CN114712497B (https=) |
| AU (4) | AU2016364817B2 (https=) |
| CA (3) | CA3137326C (https=) |
| DK (1) | DK3384049T3 (https=) |
| ES (1) | ES2956007T3 (https=) |
| FI (1) | FI3384049T3 (https=) |
| HR (1) | HRP20231379T1 (https=) |
| HU (1) | HUE063335T2 (https=) |
| IL (4) | IL295808B2 (https=) |
| LT (1) | LT3384049T (https=) |
| MX (3) | MX2018006740A (https=) |
| NZ (1) | NZ744025A (https=) |
| PL (1) | PL3384049T3 (https=) |
| PT (1) | PT3384049T (https=) |
| RS (1) | RS64725B1 (https=) |
| SI (1) | SI3384049T1 (https=) |
| SM (1) | SMT202300314T1 (https=) |
| WO (1) | WO2017096031A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2017096031A1 (en) * | 2015-12-03 | 2017-06-08 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| GB201805642D0 (en) * | 2018-04-05 | 2018-05-23 | Macusoft Ltd | Determining a clinical outcome for a subject suffering from a macular degenerative disease |
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| CN109632924B (zh) * | 2018-12-17 | 2022-02-08 | 上海市第一人民医院 | 人黄斑新生血管性疾病的血浆脂质标记物及其应用 |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| KR102625384B1 (ko) | 2020-09-28 | 2024-01-16 | (주) 플라즈닉스 | 플라즈마 토치 및 이를 이용하여 대상기체를 처리하는 방법 |
| JP7452892B2 (ja) * | 2022-06-20 | 2024-03-19 | 株式会社ニューギン | 遊技機 |
| JP7452889B2 (ja) * | 2022-06-20 | 2024-03-19 | 株式会社ニューギン | 遊技機 |
| JP7452891B2 (ja) * | 2022-06-20 | 2024-03-19 | 株式会社ニューギン | 遊技機 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03504499A (ja) | 1988-05-27 | 1991-10-03 | セントカー・インコーポレーテツド | 抗体試薬のための配合物 |
| DE4243524A1 (de) | 1992-12-22 | 1994-06-23 | Hoechst Ag | Gemische isomerer Nonanole und Decanole, ihre Herstellung, aus ihnen erhältliche Phthalsäureester und deren Verwendung als Weichmacher |
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| DE19622283A1 (de) | 1996-05-23 | 1997-11-27 | Schering Ag | Verfahren zur terminalen Sterilisierung von befüllten Spritzen |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| DE19849922A1 (de) | 1998-10-29 | 2000-05-04 | Degussa | Verfahren zur Behandlung von Basen und organische Säuren enthaltenden wäßrigen Lösungen |
| DE19849924A1 (de) | 1998-10-29 | 2000-05-04 | Degussa | Verfahren zur Abtrennung organischer Säuren aus wäßrigen Lösungen |
| US6455743B1 (en) | 1998-11-27 | 2002-09-24 | Mitsubishi Chemical Corporation | Process for producing alcohols |
| DE19914259A1 (de) | 1999-03-29 | 2000-10-05 | Basf Ag | Verfahren zur destillativen Auftrennung eines flüssigen Rohaldehydgemisches |
| US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| CN101433715B (zh) | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| DE19933348B4 (de) | 1999-07-16 | 2005-11-17 | Oxeno Olefinchemie Gmbh | Verfahren zur Reduzierung oxidischer Hydrierkontakte |
| US6777429B1 (en) | 1999-07-23 | 2004-08-17 | Novartis Ag | Ophthalmic composition |
| DE19957522A1 (de) | 1999-11-30 | 2001-05-31 | Oxeno Olefinchemie Gmbh | Verfahren zur katalytischen Durchführung von Aldolkondensationen mittels Mehrphasenreaktion |
| DE10103706A1 (de) | 2001-01-26 | 2002-08-14 | Aventis Behring Gmbh | Verwendung eines Hydrogenperoxid-Plasma-Sterilisationsverfahrens für die schonende Sterilisation temperaturempfindlicher Produkte |
| WO2003004098A1 (en) | 2001-07-06 | 2003-01-16 | Sucampo Ag | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| MXPA04000747A (es) | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| JP2005511576A (ja) | 2001-11-09 | 2005-04-28 | アイテック・ファーマシューティカルズ | 眼球血管新生病を治療する方法 |
| JP4141156B2 (ja) | 2002-03-15 | 2008-08-27 | 日本ベクトン・ディッキンソン株式会社 | プランジャ後退制限機構付きプレフィルドシリンジ |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| CA2519835A1 (en) | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection |
| WO2004110490A2 (en) | 2003-06-06 | 2004-12-23 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for tumor regression |
| WO2005016369A1 (en) | 2003-08-06 | 2005-02-24 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist in combination with radiation therapy |
| AU2005267741A1 (en) | 2004-07-30 | 2006-02-09 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
| PT1802334E (pt) | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
| JP2008520242A (ja) | 2004-11-18 | 2008-06-19 | イェール ユニバーシティ | 視覚障害を処置するための方法および組成物 |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| CA2615636A1 (en) | 2005-08-12 | 2007-02-22 | Regeneron Pharmaceuticals, Inc. | Treatment of diseases by subcutaneous administration of a vegf antagonist |
| EP1924309A1 (en) | 2005-09-16 | 2008-05-28 | (OSI) Eyetech Inc. | Ophthalmic syringe |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| EP1818069B1 (de) | 2006-02-14 | 2008-09-03 | Gerresheimer Bünde GmbH | Verfahren zum Herstellen von vorfüllbaren Spritzen |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US20100111963A1 (en) | 2006-11-10 | 2010-05-06 | Genentech, Inc. | Method for treating age-related macular degeneration |
| CN101600674B (zh) | 2006-11-30 | 2013-09-11 | 巴斯夫欧洲公司 | 烯烃的加氢甲酰化方法 |
| WO2008077155A1 (en) | 2006-12-21 | 2008-06-26 | Genentech, Inc. | Sterilization of objects containing biological molecules |
| US20100303813A1 (en) | 2007-06-08 | 2010-12-02 | Biogen Idec Ma Inc. | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| WO2009030976A1 (en) | 2007-09-03 | 2009-03-12 | Becton Dickinson France | Medical device and smooth coating therefor |
| AU2009323307B2 (en) | 2008-12-03 | 2015-02-19 | Denki Kagaku Kogyo Kabushiki Kaisha | Syringe |
| ES2600781T3 (es) * | 2008-12-04 | 2017-02-10 | Curna, Inc. | Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf |
| DE102009001594A1 (de) | 2009-03-17 | 2010-09-30 | Evonik Oxeno Gmbh | Verfahren zur Herstellung von alpha, beta-ungesättigten C10-Aldehyden |
| KR101191112B1 (ko) | 2009-03-19 | 2012-10-15 | 주식회사 엘지화학 | 고순도 2-에틸헥산올 생산을 위한 분리벽형 증류탑 및 이를 이용한 분별증류방법 |
| AR078060A1 (es) | 2009-07-14 | 2011-10-12 | Novartis Ag | Descontaminacion de superficie de contenedores previamente llenados en empaque secundario |
| DE102009045139A1 (de) | 2009-09-30 | 2011-03-31 | Evonik Oxeno Gmbh | Herstellung von alpha,beta-ungesättigten Aldehyden mittels einer Reaktionsmischpumpe |
| DE102009045718A1 (de) | 2009-10-15 | 2011-04-21 | Evonik Oxeno Gmbh | Verfahren zur Herstellung von Decanolen durch Hydrierung von Decenalen |
| MX2012004306A (es) | 2009-10-21 | 2012-04-30 | Genentech Inc | Polimorfismos geneticos en degeneracion macular relacionada con la edad. |
| CN102803189B (zh) | 2010-03-15 | 2016-01-20 | 埃克森美孚化学专利公司 | 用于生产醇的方法 |
| FR2966044B1 (fr) | 2010-10-18 | 2012-11-02 | Sanofi Pasteur | Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium |
| US8684190B2 (en) | 2010-11-19 | 2014-04-01 | Warren Abar | Multi-position solar panel rack |
| KR20190049934A (ko) | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| BR112013023724A2 (pt) * | 2011-03-15 | 2019-09-24 | Univ Utah Res Found | métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento |
| WO2013106765A1 (en) * | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
| DE202013000688U1 (de) | 2012-07-03 | 2013-03-05 | Novartis Ag | Glas-Spritze |
| KR20140042402A (ko) | 2012-09-28 | 2014-04-07 | 주식회사 엘지화학 | 올레핀으로부터 알코올의 제조장치 및 제조방법 |
| JP5721150B2 (ja) * | 2013-03-14 | 2015-05-20 | 学校法人 埼玉医科大学 | 加齢黄斑変性症の発症リスクの予測方法 |
| US9926246B2 (en) | 2013-05-03 | 2018-03-27 | Saudi Basic Industries Corporation | Integrated process for simultaneous production of oxo-alcohols and plasticizers |
| DK4374873T3 (da) | 2013-07-12 | 2025-11-03 | Astellas Us Llc | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande |
| JP6382816B2 (ja) | 2013-07-24 | 2018-08-29 | 田辺三菱製薬株式会社 | 眼科疾患治療剤 |
| DE102014201756A1 (de) | 2014-01-31 | 2015-08-06 | Evonik Degussa Gmbh | Reinigung chlorverschmutzter Organophosphorverbindungen |
| DE102014209536A1 (de) | 2014-05-20 | 2015-11-26 | Evonik Degussa Gmbh | Herstellung qualitativ hochwertiger Oxo-Alkohole aus unsteten Rohstoffquellen |
| EP3037400B1 (de) | 2014-12-23 | 2018-08-01 | Evonik Degussa GmbH | Chromfreie hydrierung von hydroformylierungsgemischen |
| EP3059005B1 (de) | 2015-02-18 | 2018-10-24 | Evonik Degussa GmbH | Abtrennung eines homogenkatalysators aus einem reaktionsgemisch mit hilfe organophiler nanofiltration unter besonderer berücksichtigung eines membran-leistungsindikators |
| SG10201601501QA (en) | 2015-03-05 | 2016-10-28 | Evonik Degussa Gmbh | Preparation of 2,2`-biaryls in the presence of molybdenum(v) chloride |
| CN104894261B (zh) * | 2015-06-02 | 2020-02-14 | 北京医院 | 一种预测雷珠单抗治疗年龄相关性黄斑变性疗效的试剂盒 |
| PL3374366T3 (pl) | 2015-11-09 | 2020-05-18 | Evonik Operations Gmbh | Bis-fosforyny z jednostkami 2,4-dimetylofenylowymi i ich zastosowanie jako ligandów w hydroformylowaniu |
| EP3170805B1 (de) | 2015-11-19 | 2018-09-12 | Evonik Degussa GmbH | Beeinflussung der viskosität von auf n-buten basierenden estergemischen durch gezielten einsatz von ethen bei der herstellung der ester-vorprodukte |
| WO2017096031A1 (en) | 2015-12-03 | 2017-06-08 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
| ES2765635T3 (es) | 2016-05-19 | 2020-06-10 | Evonik Operations Gmbh | Producción de n-pentanal a partir de mezclas de sustancias de empleo pobres en buteno |
| US10245578B2 (en) | 2016-11-09 | 2019-04-02 | Evonik Degussa Gmbh | Chromium- and nickel-free hydrogenation of hydroformylation mixtures |
| DK3351526T3 (da) | 2017-01-20 | 2021-02-08 | Evonik Operations Gmbh | Diisopentylterephthalat |
| HUE059827T2 (hu) | 2017-11-30 | 2023-01-28 | Regeneron Pharma | VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére |
-
2016
- 2016-12-01 WO PCT/US2016/064403 patent/WO2017096031A1/en not_active Ceased
- 2016-12-01 DK DK16823372.4T patent/DK3384049T3/da active
- 2016-12-01 JP JP2018528667A patent/JP6855480B2/ja active Active
- 2016-12-01 IL IL295808A patent/IL295808B2/en unknown
- 2016-12-01 EP EP25169695.1A patent/EP4559524A3/en active Pending
- 2016-12-01 ES ES16823372T patent/ES2956007T3/es active Active
- 2016-12-01 NZ NZ744025A patent/NZ744025A/en unknown
- 2016-12-01 CA CA3137326A patent/CA3137326C/en active Active
- 2016-12-01 LT LTEPPCT/US2016/064403T patent/LT3384049T/lt unknown
- 2016-12-01 IL IL315458A patent/IL315458A/en unknown
- 2016-12-01 EP EP23180558.1A patent/EP4276199A3/en active Pending
- 2016-12-01 KR KR1020187017681A patent/KR102183910B1/ko active Active
- 2016-12-01 KR KR1020217041649A patent/KR20210157427A/ko not_active Ceased
- 2016-12-01 CA CA3007276A patent/CA3007276C/en active Active
- 2016-12-01 CA CA3179836A patent/CA3179836A1/en active Pending
- 2016-12-01 RS RS20230978A patent/RS64725B1/sr unknown
- 2016-12-01 PT PT168233724T patent/PT3384049T/pt unknown
- 2016-12-01 PL PL16823372.4T patent/PL3384049T3/pl unknown
- 2016-12-01 CN CN202210521088.6A patent/CN114712497B/zh active Active
- 2016-12-01 HU HUE16823372A patent/HUE063335T2/hu unknown
- 2016-12-01 AU AU2016364817A patent/AU2016364817B2/en active Active
- 2016-12-01 SM SM20230314T patent/SMT202300314T1/it unknown
- 2016-12-01 EP EP16823372.4A patent/EP3384049B1/en active Active
- 2016-12-01 CN CN201680070835.1A patent/CN108474039B/zh active Active
- 2016-12-01 KR KR1020207012363A patent/KR102261636B1/ko active Active
- 2016-12-01 FI FIEP16823372.4T patent/FI3384049T3/fi active
- 2016-12-01 MX MX2018006740A patent/MX2018006740A/es unknown
- 2016-12-01 KR KR1020217016566A patent/KR102343004B1/ko active Active
- 2016-12-01 SI SI201631732T patent/SI3384049T1/sl unknown
- 2016-12-01 IL IL302424A patent/IL302424B2/en unknown
- 2016-12-01 HR HRP20231379TT patent/HRP20231379T1/hr unknown
-
2018
- 2018-05-29 IL IL259672A patent/IL259672B2/en unknown
- 2018-06-01 MX MX2023008504A patent/MX2023008504A/es unknown
- 2018-06-01 MX MX2023004922A patent/MX2023004922A/es unknown
- 2018-06-01 US US15/995,518 patent/US11769597B2/en active Active
-
2020
- 2020-05-22 AU AU2020203362A patent/AU2020203362B2/en active Active
-
2021
- 2021-03-17 JP JP2021043218A patent/JP7233754B2/ja active Active
-
2022
- 2022-09-20 AU AU2022235529A patent/AU2022235529B2/en active Active
- 2022-09-20 AU AU2022235531A patent/AU2022235531B2/en active Active
-
2023
- 2023-02-15 JP JP2023021608A patent/JP7429318B2/ja active Active
- 2023-08-15 US US18/234,101 patent/US20240029897A1/en active Pending
-
2024
- 2024-01-26 JP JP2024010498A patent/JP7661545B2/ja active Active
-
2025
- 2025-04-02 JP JP2025060904A patent/JP2025096332A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3384049T3 (fi) | Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä | |
| Lozada-Delgado et al. | RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials | |
| US9242000B2 (en) | Micro-RNAs and micro-RNA inhibitors to modulate blood vessel growth, patterning, tumor growth and malignant disease and method for making and using them | |
| Panis et al. | Cytokines as mediators of pain‐related process in breast cancer | |
| JP2019524768A5 (https=) | ||
| JP2018508469A5 (https=) | ||
| JP2017532961A5 (https=) | ||
| Yan et al. | Influence of component 5a receptor 1 (C5AR1)− 1330T/G polymorphism on nonsedating H1-antihistamines therapy in Chinese patients with chronic spontaneous urticaria | |
| Kim et al. | OCT-1, ABCB1, and ABCG2 expression in imatinib-resistant chronic myeloid leukemia treated with dasatinib or nilotinib | |
| HRP20191145T1 (hr) | Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak | |
| US20210395833A1 (en) | Methods of identifying risk of bevacizumab-induced proteinuria and hypertension | |
| Falduto et al. | How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma | |
| Zhao et al. | Proangiogenic role of circRNA‐007371 in liver fibrosis | |
| Hengeveld et al. | Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110 | |
| Garcia-Moruja et al. | Molecular Phenotype of CXCL12β 3'UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression | |
| Li et al. | Molecular cloning, characterization and expression of miR-15a-3p and miR-15b-3p in dairy cattle | |
| Guzmán-Flores et al. | Molecular mechanism of curcumin on periodontitis: A pharmacological network study | |
| Ming-Zhong et al. | Genetic variants of the DNA damage repair genes XRCC4 and RAD51 are associated with susceptibility to esophageal cancer | |
| RU2014123166A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| Choi et al. | Lack of association between DRD2 Taq1A gene polymorphism and smoking cessation therapy: a meta-analysis | |
| NZ761246B2 (en) | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF | |
| NZ761242B2 (en) | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF | |
| Joseph et al. | Genetic evidence that a gut commensal bacterium can cause colorectal cancer | |
| Giersch et al. | Sureau C, Casey J, Huang J, Fischer N, Lütgehetmann M and Dandri M (2021) Strong Replication Interference Between Hepatitis Delta Viruses in Human Liver Chimeric Mice | |
| Stamatis-Liossis et al. | Is there a link between IL-23/IL-17 and developmental pathways such as the Wnt and Hedgehog pathway? |